Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) – Jefferies Group issued their Q1 2018 earnings per share (EPS) estimates for Intercept Pharmaceuticals in a research note issued to investors on Wednesday. Jefferies Group analyst M. Yee expects that the biopharmaceutical company will earn ($3.30) per share for the quarter. Jefferies Group has a “Buy” rating and a $135.00 price objective on the stock. Jefferies Group also issued estimates for Intercept Pharmaceuticals’ Q2 2018 earnings at ($3.17) EPS, Q3 2018 earnings at ($3.08) EPS, Q4 2018 earnings at ($2.85) EPS and FY2019 earnings at ($10.16) EPS.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative return on equity of 152.78% and a negative net margin of 344.74%. The business had revenue of $41.33 million for the quarter, compared to the consensus estimate of $36.95 million. During the same period last year, the business posted ($3.59) EPS. The business’s revenue was up 697.9% compared to the same quarter last year. TRADEMARK VIOLATION NOTICE: This piece was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.com-unik.info/2017/11/04/research-analysts-issue-forecasts-for-intercept-pharmaceuticals-inc-s-q1-2018-earnings-icpt.html.
Other analysts have also issued research reports about the stock. BidaskClub raised shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 13th. Zacks Investment Research upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $136.00 target price on the stock in a report on Tuesday, July 11th. Wedbush reiterated a “buy” rating on shares of Intercept Pharmaceuticals in a report on Monday, July 31st. Cowen and Company reiterated a “buy” rating and issued a $112.00 price objective (down from $232.00) on shares of Intercept Pharmaceuticals in a report on Friday, September 22nd. Finally, Seaport Global Securities restated a “buy” rating and issued a $136.00 price target on shares of Intercept Pharmaceuticals in a research note on Friday, October 6th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $153.76.
Intercept Pharmaceuticals (ICPT) opened at $65.09 on Thursday. The company has a current ratio of 6.61, a quick ratio of 6.61 and a debt-to-equity ratio of 2.05.
Hedge funds have recently made changes to their positions in the company. Sphera Funds Management LTD. grew its position in shares of Intercept Pharmaceuticals by 100.0% during the 2nd quarter. Sphera Funds Management LTD. now owns 30,000 shares of the biopharmaceutical company’s stock worth $3,632,000 after buying an additional 15,000 shares during the period. Vanguard Group Inc. grew its position in shares of Intercept Pharmaceuticals by 4.5% during the 2nd quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock worth $160,797,000 after buying an additional 57,149 shares during the period. Oppenheimer & Co. Inc. grew its position in shares of Intercept Pharmaceuticals by 9.0% during the 1st quarter. Oppenheimer & Co. Inc. now owns 2,152 shares of the biopharmaceutical company’s stock worth $244,000 after buying an additional 178 shares during the period. Dynamic Technology Lab Private Ltd grew its position in shares of Intercept Pharmaceuticals by 85.6% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 6,798 shares of the biopharmaceutical company’s stock worth $824,000 after buying an additional 3,136 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Intercept Pharmaceuticals by 12.8% during the 1st quarter. Geode Capital Management LLC now owns 144,130 shares of the biopharmaceutical company’s stock worth $16,301,000 after buying an additional 16,392 shares during the period. 82.81% of the stock is owned by institutional investors.
In other news, CEO Mark Pruzanski sold 1,532 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $58.87, for a total transaction of $90,188.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Lisa Bright sold 253 shares of the firm’s stock in a transaction that occurred on Friday, August 25th. The stock was sold at an average price of $111.31, for a total transaction of $28,161.43. Following the sale, the insider now directly owns 23,324 shares of the company’s stock, valued at approximately $2,596,194.44. The disclosure for this sale can be found here. Insiders have sold a total of 4,069 shares of company stock valued at $325,974 in the last three months. Insiders own 9.20% of the company’s stock.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
What are top analysts saying about Intercept Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intercept Pharmaceuticals Inc. and related companies.